Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182959 | 0.81 | LMNA (0.42) | LMNAHTTPOLBGALR3MAPT | |
| SCHEMBL4180979 | 0.79 | LMNA (0.47) | LMNAHTTPOLBGALR3MAPT | |
| SCHEMBL4181344 | 0.78 | PPARD (0.49) | HTTPOLBALDH1A1KDM4EKMT2A | |
| SCHEMBL4179912 | 0.76 | POLB (0.42) | LMNAHTTPOLBGALR3MAPT | |
| SCHEMBL24091309 | 0.74 | LMNA (0.46) | LMNAHTTPOLBGALR3MAPT | |
| SCHEMBL4185294 | 0.73 | LMNA (0.51) | LMNAHTTPOLBMAPTSMN1; SMN2 | |
| SCHEMBL4183137 | 0.72 | LMNA (0.50) | LMNAHTTPOLBMAPTSMN1; SMN2 | |
| SCHEMBL4182940 | 0.71 | PTGDR2 (0.45) | LMNAHTTKMT2ATSHR | |
| SCHEMBL1948781 | 0.71 | SMN1; SMN2 (0.58) | LMNAHTTPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL18791371 | 0.71 | GAA (0.51) | LMNAHTTPOLBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| EP-1945620-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056366-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARA, PPARD | LMNA 1383/4885HTT 1136/4885POLB 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.